RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA

被引：0
|
作者：
Izzo, G. Nitrato [1 ]
Villa, M. R. [1 ]
Gagliardi, A. [1 ]
Improta, S. [1 ]
Mastrullo, L. [1 ]
机构：
[1] ASL Napoli 1 Ctr, PO San Gennaro, UOC Ematol, Naples, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P042
引用
收藏
页码：74 / 75
页数：2
相关论文
共 50 条
  • [1] BENDAMUSTINE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA (WM)
    Improta, S.
    Villa, M.
    Gagliardi, A.
    Lucania, A.
    Della Cioppa, P.
    Esposito, M.
    Mastrullo, L.
    HAEMATOLOGICA, 2013, 98 : 638 - 638
  • [2] Bendamustine Therapy in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
    Treon, Steven P.
    Hanzis, Christina
    Tripsas, Christina
    Ioakimidis, Leukothea
    Patterson, Christopher J.
    Manning, Robert J.
    Sheehy, Patricia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 133 - 135
  • [3] Bendamustine plus rituximab for the treatment of Waldenstrom Macroglobulinemia: Patient outcomes and impact of bendamustine dosing
    Arulogun, Suzanne O.
    Brian, Duncan
    Goradia, Harshita
    Cooney, Aaron
    Menne, Tobias
    Koo, RayMun
    O'Neill, Aideen T.
    Vos, Josephine M. I.
    Pratt, Guy
    Turner, Deborah
    Marshall, Kirsty
    Manos, Kate
    Anderson, Claire
    Gavriatopoulou, Maria
    Kyriakou, Charalampia
    Kersten, Marie J.
    Minnema, Monique C.
    Koutoumanou, Eirini
    El-Sharkawi, Dima
    Linton, Kim
    Talaulikar, Dipti
    McCarthy, Helen
    Bishton, Mark
    Follows, George
    Wechalekar, Ashutosh
    D'Sa, Shirley P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (05) : 750 - 759
  • [4] Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia
    Ghobrial, Irene M.
    Boswell, Erica N.
    Banwait, Ranjit
    Poon, Tiffany
    Donovan, Amanda
    Chuma, Stacey
    Kunsman, Janet
    Warren, Diane
    Bagshaw, Meghan
    Anderson, Kenneth C.
    Richardson, Paul G.
    Treon, Steven
    BLOOD, 2011, 118 (21) : 1163 - 1164
  • [5] Bortezomib in Relapsed or Refractory Waldenstrom's Macroglobulinemia
    Chen, Christine
    Kouroukis, C. Tom
    White, Darrell
    Voralia, Michael
    Stadtmauer, Edward
    Stewart, A. Keith
    Wright, John J.
    Powers, Jean
    Walsh, Wendy
    Eisenhauer, Elizabeth
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (01): : 74 - 76
  • [6] The Management of Relapsed or Refractory Waldenstrom's Macroglobulinemia
    Garcia-Sanz, Ramon
    Tedeschi, Alessandra
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (04) : 727 - 749
  • [7] Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemia
    Paludo, Jonas
    Abeykoon, Jithma P.
    Kumar, Shaji
    Shreders, Amanda
    Ailawadhi, Sikander
    Gertz, Morie A.
    Kourelis, Taxiarchis
    King, Rebecca L.
    Reeder, Craig B.
    Leung, Nelson
    Kyle, Robert A.
    Buadi, Francis K.
    Habermann, Thomas M.
    Dingli, David
    Witzig, Thomas E.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Warsame, Rahma
    Lust, John A.
    Rajkumar, S. Vincent
    Ansell, Stephen M.
    Kapoor, Prashant
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (01) : 98 - 105
  • [8] Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM)
    Paludo, Jonas
    Abeykoon, Jithma P.
    Hesse, Amber B.
    Shreders, Amanda
    Ailawadhi, Sikander
    Ansell, Stephen
    Gertz, Morie A.
    Reeder, Craig B.
    King, Rebecca L.
    Kyle, Robert A.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Habermann, Thomas M.
    Dingli, David
    Witzig, Thomas E.
    Go, Ronald S.
    Gonsalves, Wilson I.
    Leung, Nelson
    Lin, Yi
    Lust, John A.
    Rajkumar, S. Vincent
    Kumar, Shaji
    Kapoor, Prashant
    BLOOD, 2016, 128 (22)
  • [9] Phase II Trial of Bortezomib and Rituximab in Relapsed/Refractory Waldenstrom Macroglobulinemia
    Ghobrial, I. M.
    Roccaro, A. M.
    Matous, J.
    Padmanabhan, W.
    Badros, A.
    Schlossman, R.
    Chuma, S.
    Leduc, R.
    Nelson, M.
    O'Connor, K.
    Sam, A.
    Harris, B.
    Soumerai, J.
    Warren, D.
    Birner, A.
    Munshi, N. C.
    Treon, S. P.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S83 - S84
  • [10] Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients
    Zhou, Daobin
    Jin, Jie
    Fu, Zheng-zheng
    Yi, Shuhua
    Zhao, Wei Li
    Sun, Zimin
    Yang, Wei
    Li, Dengju
    Cui, Guohui
    Hu, Jianda
    Liu, Ting
    Song, Yongping
    Xu, Bing
    Zhu, Zunmin
    Xu, Wei
    Zhang, Mingzhi
    Tian, Yamin
    Zhu, Huaqiang
    Zhang, Bin
    Zhao, Renbin
    Zhang, Xiang-Yang
    BLOOD, 2021, 138
12345